Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.03B | 4.03B | 4.86B | 5.63B | 3.78B |
Gross Profit | 2.23B | 2.07B | 3.00B | 3.80B | 2.23B |
EBITDA | 1.30B | 1.11B | 2.11B | 2.86B | 1.50B |
Net Income | 789.50M | 456.00M | 1.30B | 1.87B | 1.12B |
Balance Sheet | |||||
Total Assets | 9.16B | 9.14B | 9.07B | 8.92B | 7.20B |
Cash, Cash Equivalents and Short-Term Investments | 2.33B | 2.72B | 2.34B | 1.17B | 701.00M |
Total Debt | 2.66B | 2.82B | 2.82B | 3.03B | 3.04B |
Total Liabilities | 4.03B | 4.12B | 4.20B | 4.70B | 4.49B |
Stockholders Equity | 5.13B | 5.02B | 4.88B | 4.22B | 2.71B |
Cash Flow | |||||
Free Cash Flow | 1.15B | 901.00M | 2.00B | 2.17B | 740.20M |
Operating Cash Flow | 1.29B | 1.05B | 2.13B | 2.33B | 896.60M |
Investing Cash Flow | -781.00M | -152.10M | -206.30M | -1.33B | -141.60M |
Financing Cash Flow | -1.11B | -483.20M | -756.00M | -529.80M | -659.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
83 Outperform | $40.08B | 30.69 | 25.81% | 0.78% | 9.54% | 37.23% | |
73 Outperform | $14.64B | 35.59 | 5.15% | ― | 6.88% | 21.11% | |
72 Outperform | $16.33B | 35.70 | 17.72% | 0.30% | -1.14% | -16.35% | |
70 Outperform | $14.70B | 27.85 | 11.77% | ― | 1.66% | 21.95% | |
70 Outperform | $52.33B | 34.84 | 5.97% | 2.22% | 5.84% | 15.12% | |
60 Neutral | HK$16.84B | 5.17 | -7.44% | 2.89% | 11.55% | -28.15% | |
56 Neutral | $14.66B | 136.07 | -8.96% | 2.78% | -20.17% | -138.32% |
On July 15, 2025, Hologic, Inc. and its subsidiaries refinanced their term loan and revolving credit facility by entering into a Refinancing Amendment to their existing Credit and Guaranty Agreement. This amendment extends the maturity date to July 15, 2030, and provides additional financial flexibility under certain covenants, impacting the company’s operational capabilities and financial strategy.
The most recent analyst rating on (HOLX) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.